Cervical Cancer

Cervical cancer is a malignant neoplasm originating from the epithelial cells of the uterine cervix—the lower, anatomical neck of the uterus that connects the uterine cavity to the vagina. It is the fourth most common cancer diagnosed in women worldwide, with approximately 660,000 new cases and 350,000 deaths annually (World Health Organization, 2022).

Virtually all cervical malignancies are caused by persistent, high-risk human papillomavirus (HR-HPV) infection, primarily genotypes 16 and 18. Despite its substantial global disease burden, cervical cancer is one of the most preventable and curable human malignancies when detected early through organized screening (HPV DNA testing and Pap cytology) or prevented through primary prophylactic HPV vaccination.

The uterine cervix is divided into two distinct anatomical regions: the ectocervix, which protrudes into the vagina and is covered by stratified non-keratinizing squamous epithelium, and the endocervical canal, lined by single-layered mucus-secreting columnar epithelium.

The Cervical Transformation Zone

The junction between the squamous and columnar epithelia is known as the squamocolumnar junction (SCJ). Physiological metaplasia occurs dynamically within this zone over a woman's lifetime, creating the transformation zone (TZ). Because actively dividing, immature metaplastic epithelial cells reside here, the transformation zone is the primary anatomical site where high-risk HPV integrations occur and where over 90% of cervical precancerous lesions and invasive carcinomas originate.

Recognized Histopathological Subtypes

• Squamous Cell Carcinoma (SCC): Accounts for approximately 75% to 80% of all cervical cancers. Arises from the ectocervix or squamous cells of the transformation zone.
• Adenocarcinoma: Accounts for approximately 20% to 25% of cases. Arises from mucus-secreting glandular cells lining the endocervical canal. Its relative incidence has increased over recent decades. Due to its location deeper within the endocervix, it is often more challenging to detect on surface cytology alone.
• Adenosquamous Carcinoma: A mixed malignancy containing both malignant squamous and glandular components, representing approximately 3% to 5% of cases, typically carrying a more aggressive clinical course.
• Neuroendocrine Cervical Carcinoma: A rare (<2%), highly aggressive variant (including small cell and large cell neuroendocrine carcinomas) characterized by early hematogenous and lymph node dissemination requiring multimodal systemic chemotherapy.

In its pre-invasive and earliest microinvasive stages, cervical cancer is almost universally asymptomatic. This makes routine population screening essential, as waiting for physical symptoms to appear generally corresponds to invasive disease progression.

Cardinal Early-Stage Symptoms

• Abnormal Vaginal Bleeding: The most frequent clinical manifestation. It most characteristically presents as postcoital contact bleeding (bleeding after sexual intercourse), but also manifests as intermenstrual spotting (bleeding between regular periods) or unexpected postmenopausal bleeding.
• Unusual Vaginal Discharge: Persistent watery, serosanguinous (pale pink/brown), or foul-smelling vaginal discharge that is refractory to standard antimicrobial therapy for vaginitis.
• Pelvic Discomfort or Dyspareunia: Deep pelvic aching, lower abdominal pressure, or pain during sexual intercourse.

Advanced & Locally Invasive Symptoms

As the tumor infiltrates through the cervical stroma into adjacent pelvic structures, parametria, pelvic sidewall, or neural plexuses, additional signs emerge:

• Persistent Lower Back or Flank Pain: Caused by tumor extension into the cardinal ligaments compressing the ureters, causing urinary outflow obstruction and unilateral or bilateral hydronephrosis.
• Unilateral Lower Extremity Edema: Asymmetric swelling in one leg resulting from tumor mass compression of the external/internal iliac veins or extensive pelvic lymphatic blockage.
• Urinary and Rectal Symptoms: Hematuria (blood in urine), urinary frequency, dysuria, hematochezia (rectal bleeding), tenesmus, or the involuntary passage of urine or stool through the vagina due to vesicovaginal or rectovaginal fistula formation.
• Systemic Manifestations: Unexplained significant weight loss, chronic cachexia, severe fatigue, and symptomatic microcytic anemia from ongoing tumor bleeding.

The essential causative agent of cervical cancer is persistent infection with High-Risk Human Papillomavirus (HR-HPV). Human papillomavirus is a non-enveloped, double-stranded circular DNA virus that selectively infects basal epithelial keratinocytes.

High-Risk Genotypes vs. Low-Risk Genotypes

• Oncogenic High-Risk Types: Genotypes HPV 16 and HPV 18 are responsible for approximately 70% of all cervical cancers worldwide. An additional five high-risk types (HPV 31, 33, 45, 52, and 58) account for another 20% of cases.
• Non-Oncogenic Low-Risk Types: Genotypes HPV 6 and HPV 11 cause over 90% of benign anogenital warts (condylomata acuminata) and low-grade mucosal lesions, but do not cause cervical cancer.

Molecular Pathogenesis: E6 and E7 Viral Oncoproteins

During persistent high-risk HPV infection, the viral episome integrates into the host cell genome, disrupting the viral E2 regulatory gene. This unleashes continuous, unchecked expression of two potent viral oncoproteins:

• E6 Oncoprotein: Binds to the host ubiquitin ligase E6AP, recruiting it to degrade the p53 tumor suppressor protein. Loss of p53 abolishes the cell's capacity for DNA repair and programmed cell death (apoptosis) in response to genetic damage.
• E7 Oncoprotein: Binds and inactivates the retinoblastoma tumor suppressor protein (pRb). Under normal conditions, hypophosphorylated pRb sequesters the E2F transcription factor. E7 disrupts this binding, releasing free E2F to drive uncontrolled progression through the G1/S cell cycle checkpoint.

Natural History, Latency & Contagion Clarification

Transmission of HPV: HPV is the most common sexually transmitted infection globally, acquired through intimate skin-to-skin contact and sexual intercourse. Over 80% to 90% of sexually active individuals acquire HPV at some point in their lives. In the vast majority of immunocompetent individuals (90%), the host cell-mediated immune system clears the transient viral infection within 12 to 24 months without cellular harm or neoplastic transformation.

Latency: True malignant transformation requires persistent high-risk HPV infection over an extended latency window—typically spanning 10 to 20 years from initial infection through precancerous cervical intraepithelial neoplasia (CIN 1, CIN 2, CIN 3) to invasive carcinoma. In immunocompromised individuals (such as those living with HIV), this progression can occur within 5 to 10 years.

While high-risk HPV infection is the necessary cause of cervical cancer, HPV alone is not always sufficient; the majority of HPV infections clear spontaneously. Specific cofactors influence whether an infection persists and progresses to invasive malignancy:

Complications of cervical cancer stem from local pelvic invasion, vascular erosion, nerve compression, distant metastatic spread, and late toxicities of extensive oncologic therapies:

The clinical evaluation of cervical cancer requires a clear distinction between screening (population-level detection in asymptomatic individuals), diagnostic confirmation (histopathologic tissue biopsy), and staging investigations (determining disease extent to guide therapy).

Treatment for cervical cancer is strictly stage-dependent, determined by the FIGO 2018 stage, tumor size, lymph node status, and the patient's desire for future fertility preservation.

1. Microinvasive Early Stage (FIGO IA1)

• Fertility-Sparing Management: Conization (LEEP or Cold Knife Cone Biopsy) with negative surgical margins (>=3mm) without lymphovascular space invasion (LVSI) is curative and preserves the uterine body.
• Non-Fertility Sparing: Simple total extrafascial hysterectomy for patients who have completed childbearing.

2. Early Invasive Disease (FIGO IA2, IB1, IB2, IIA1 — Tumors ≤4 cm)

• Radical Hysterectomy with Bilateral Pelvic Lymphadenectomy: Surgical resection of the uterus, cervix, upper 1–2 cm of the vagina, and surrounding parametrial tissue, accompanied by systemic pelvic lymph node dissection. Ovarian preservation is safe and feasible in premenopausal patients with squamous cell histology.
• Radical Trachelectomy (Fertility-Sparing): For women aged <45 wishing to preserve fertility with lesions ≤2 cm (Stage IA2 to IB1) and negative pelvic lymph nodes. The cervix and parametria are removed while preserving the uterine corpus, with placement of a permanent prophylactic cervical cerclage.
• Adjuvant Therapy: If pathology demonstrates intermediate-risk factors (Sedlis criteria: large tumor, deep stromal invasion, LVSI) or high-risk factors (Peters criteria: positive surgical margins, positive lymph nodes, parametrial involvement), postoperative pelvic radiation or concurrent chemoradiation is administered.

3. Locally Advanced Cervical Cancer (FIGO IB3, IIA2, IIB, III, IVA)

Definitive Concurrent Chemoradiotherapy (CCRT): The global gold-standard standard of care for locally advanced cervical cancer. Primary surgery is contraindicated in Stage IIB and higher due to lack of survival benefit and excessive combined morbidity.

• External Beam Radiation Therapy (EBRT): High-precision intensity-modulated radiation therapy (IMRT) delivering 45–50 Gy in 25–28 fractions to the pelvis (+/- extended field to para-aortic nodes if involved).
• Concurrent Weekly Cisplatin: Radiosensitizing cisplatin chemotherapy (40 mg/m² weekly for 5–6 cycles during radiation).
• Image-Guided Adaptive Brachytherapy (IGABT): Crucial high-dose intracavitary/interstitial radiation delivered directly into the cervical tumor over 4–5 fractions using MRI or CT planning, escalating total tumor dose to >80–85 Gy EQD2 while minimizing dose to bladder, rectum, and sigmoid.

4. Metastatic & Recurrent Disease (FIGO IVB)

Managed with systemic multi-agent palliative pharmacotherapy:

• First-Line Systemic Triplet/Quadruplet Therapy: Platinum doublet chemotherapy (Cisplatin + Paclitaxel or Carboplatin + Paclitaxel) combined with Bevacizumab (anti-VEGF monoclonal antibody targeting tumor angiogenesis) plus Pembrolizumab (anti-PD-1 immunotherapy) for tumors expressing PD-L1 (CPS ≥1), based on the landmark KEYNOTE-826 phase III trial.
• Second-Line Targeted Therapy: Tisotumab vedotin, a tissue factor-directed antibody-drug conjugate (ADC) delivering monomethyl auristatin E (MMAE), for patients with disease progression on or after frontline platinum therapy.

Cervical cancer is unique among major malignancies because primary prevention through vaccination and secondary prevention through screening can theoretically eliminate it as a public health problem (WHO Elimination Initiative target of <4 cases per 100,000 women).

Primary Prevention: Prophylactic HPV Vaccination

• 9-Valent HPV Vaccine (Gardasil 9): Protects against seven high-risk oncogenic genotypes (HPV 16, 18, 31, 33, 45, 52, 58) that cause ~90% of cervical cancers, plus low-risk genotypes 6 and 11 that cause anogenital warts.
• Recommended Vaccination Schedule:
  • Ages 9 to 14 Years: 2-dose series administered at 0 and 6–12 months. Efficacy is highest when administered prior to sexual debut and initial viral exposure.
  • Ages 15 to 26 Years: 3-dose series administered at 0, 1–2, and 6 months for individuals not vaccinated earlier.
  • Ages 27 to 45 Years: Clinical shared decision-making for adults who may benefit based on new exposure risks.
• Vaccination of Boys & Men: Routinely recommended for boys and young men to reduce viral transmission and prevent HPV-associated penile, anal, and oropharyngeal cancers.

Secondary Prevention & Protective Lifestyle Measures

• Adherence to Organized Screening: Vaccinated individuals must still undergo regular cervical screening because the vaccine does not protect against all rare oncogenic types and does not treat pre-existing infections.
• Prompt Management of Precancer (CIN 2/3): Timely outpatient excisional (LEEP) or ablative treatment of high-grade intraepithelial lesions prevents progression to invasive carcinoma.
• Consistent Barrier Contraception: Consistent condom use reduces human papillomavirus transmission by approximately 70% and protects against mucosal co-infections.
• Tobacco Smoking Cessation: Stopping smoking restores mucosal Langerhans dendritic cell immunity in cervical stroma, halving persistent dysplasia risk.

Following definitive treatment, patients transition into structured long-term survivorship care to monitor for recurrence, manage treatment toxicities, and optimize functional quality of life.

Post-Treatment Surveillance Schedule (NCCN / SGO Guidelines)

• Years 1 & 2: Clinical history and physical examination (including careful speculum, bimanual, and rectovaginal palpation) every 3 to 4 months. Approximately 75% of recurrences occur within the first 24 months.
• Years 3 to 5: Clinical evaluation every 6 months.
• After 5 Years: Annual comprehensive physical and wellness examination.
• Imaging Surveillance Rules: Routine annual imaging (CT/PET/MRI) in asymptomatic patients is not recommended without clinical symptoms or abnormal physical examination findings. PET/CT is typically obtained once at 3–6 months post-CCRT to confirm complete metabolic response.

Survivorship & Quality of Life Management

• Vaginal Health & Dilator Therapy: Pelvic radiotherapy and brachytherapy cause microvascular fibrosis and vaginal mucosal agglutination (shortening and stenosis). Regular use of medical vaginal dilators with water-soluble lubricants, initiated 2 to 4 weeks after completing radiation, prevents vaginal stenosis and preserves sexual function and pelvic examination access.
• Premature Menopause & Sexual Health: Oophorectomy or pelvic radiation destroys ovarian follicular reserve in premenopausal women, inducing sudden surgical/radiation menopause. Low-dose localized vaginal estrogen or systemic hormone therapy should be discussed with the oncology team.
• Radiation Bowel & Bladder Toxicities: Chronic radiation proctitis (rectal bleeding, tenesmus) and radiation cystitis (dysuria, hematuria) can occur months to years later and require specialized gastroenterology/urology co-management.
• Lymphedema Care: Patients experiencing lower extremity swelling following pelvic lymph node dissection should receive prompt certified lymphedema therapy (manual lymphatic drainage, graduated compression hosiery).